Leerink Partners Initiates Coverage on Attovia Therapeutics (NASDAQ:ATTO)

Stock analysts at Leerink Partners initiated coverage on shares of Attovia Therapeutics (NASDAQ:ATTO) in a research report issued to clients and investors on Monday. The brokerage set an “outperform” rating and a $52.00 price target on the stock. Leerink Partners’ price target would suggest a potential upside of 151.21% from the company’s current price.

Separately, Morgan Stanley began coverage on Attovia Therapeutics in a report on Monday. They issued an “overweight” rating and a $39.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $41.50.

Attovia Therapeutics Price Performance

Shares of NASDAQ ATTO opened at $20.70 on Monday. Attovia Therapeutics has a 1 year low of $16.15 and a 1 year high of $24.32.

Insider Buying and Selling

In other Attovia Therapeutics news, Director Colin Walsh bought 500,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $8,500,000.00. Following the acquisition, the director directly owned 3,020,632 shares of the company’s stock, valued at $51,350,744. This trade represents a 19.84% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Goldman Sachs Group Inc bought 500,000 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average cost of $17.00 per share, with a total value of $8,500,000.00. Following the completion of the purchase, the insider owned 3,020,632 shares of the company’s stock, valued at approximately $51,350,744. The trade was a 19.84% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have acquired 2,740,587 shares of company stock worth $47,269,979.

Hedge Funds Weigh In On Attovia Therapeutics

A hedge fund recently raised its position in Attovia Therapeutics stock. BlackRock Inc. increased its stake in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent quarter.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.